Novartis' Mereo selects Icon as exclusive provider of development services
Spun out from Novartis with three mid- to late-stage biologics, UK-based Mereo is initially targeting brittle bone syndrome, acute exacerbations of chronic obstructive pulmonary disease and hypogonadotropic hypogonadism.
Mereo CEO Denise Scots-Knight said: “The relationship is designed not only to help us conduct global clinical studies as we develop our product portfolio, but also to leverage Icon’s broader consulting expertise. We look forward to a fruitful alliance, progressing our pipeline in the clinic and ultimately delivering new valuable medicines to patients.”
Ciaran Murray, CEO of Icon, added: “We are delighted to have been selected as Mereo’s clinical development partner. We look forward to helping Mereo accelerate the development of their pipeline and bring to market drugs that will enhance the quality of patients’ lives.”
